Accustem Sciences Inc. Insider Trading
ACUT
No open-market buying or selling by insiders.
The last open-market buy by an executive or director was in Jun 2025.
Get an email when ACUT's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Jun 13, 2025 | Gabriele M Cerrone Director | Bought 2 parts | 2,400 | $1.02 average | 2K | <0.1% | Form 4 |
| Jun 11, 2025 – Jun 12, 2025 | Gabriele M Cerrone Director | Bought 2 parts | 37,196 | $0.50 average | 18K | 0.6% | Form 4 |
| Apr 8, 2025 – Apr 9, 2025 | Gabriele M Cerrone Director | Bought 2 parts | 38,000 | $0.67 average | 25K | 0.8% | Form 4 |
| Mar 18, 2025 – Apr 7, 2025 | Gabriele M Cerrone Director | Bought 3 parts | 152,802 | $0.51 average | 79K | 3.2% | Form 4 |
| Dec 31, 2024 | Gabriele M Cerrone Director | Bought | 100,000 | $0.38 | 38K | 2.2% | Form 4 |
- Jun 13, 2025Gabriele M CerroneDirector · bought 2,400 at avg $1.022K<0.1% of stake
- Jun 11, 2025 – Jun 12, 2025Gabriele M CerroneDirector · bought 37,196 at avg $0.5018K0.6% of stake
- Apr 8, 2025 – Apr 9, 2025Gabriele M CerroneDirector · bought 38,000 at avg $0.6725K0.8% of stake
- Mar 18, 2025 – Apr 7, 2025Gabriele M CerroneDirector · bought 152,802 at avg $0.5179K3.2% of stake
- Dec 31, 2024Gabriele M CerroneDirector · bought 100,000 at $0.3838K2.2% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with ACUT
Spot a number that looks wrong? Check it in ACUT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ACUT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.